Table 3. Mean, std deviations in (), number of subjects for the primary and secondary measures of the randomized phase, with short and long term f/u. Recalcitrant EE subjects allowed to choose Astym at 8 wks.
| DASH EE | DASH Astym | VAS active (mm) EE | VAS active (mm) Astym | Function (mm) EE | Function (mm) Astym | Max grip (lbs) EE | Max grip (lbs) Astym | |
|---|---|---|---|---|---|---|---|---|
| Randomized phase | ||||||||
| Baseline | 29.8 (14.6) | 29.5 (14.5) | 53 (25) | 59 (24) | 62 (25) | 59 (25) | 58.1 (30.8) | 70.3 (35.1) |
| N = 56 | N = 57 | N = 50 | N = 52 | N = 45 | N = 50 | N = 48 | N = 55 | |
| 4 weeks | 19.7 (11.4) | 15.4 (10.9) | 41 (24) | 37 (25) | 73 (24) | 76 (21) | 60.1 (35.9) | 80.1 (33.5) |
| N = 44 | N = 46 | N = 44 | N = 44 | N = 43 | N = 45 | N = 42 | N = 43 | |
| Gain scores 0–4 weeks | ↓7.8(13.2) | ↓13.3(12.9) | ↓13.3(28) | ↓24(27) | ↑12(28) | ↑16(28) | ↓1.9(15.9) | ↑8.9(18.6) |
| N = 44 | N = 46 | N = 40 | N = 40 | N = 35 | N = 40 | N = 38 | N = 41 | |
| Short term follow-up | ||||||||
| 8 weeks | 19.4 (12.1) | 17.3 (12.7) | 38 (25) | 43 (29) | 73 (22) | 78 (23) | 57.8 (31.6) | 68.2 (38.2) |
| N = 30 | N = 15 | N = 29 | N = 14 | N = 30 | N = 14 | N = 28 | N = 13 | |
| 12 weeks | 9.3 (6.7) | NA | 17 (19) | NA | 85 (15) | NA | 62.7 (33.8) | NA |
| N = 18 | N = 1 | N = 19 | N = 1 | N = 19 | N = 1 | N = 17 | N = 1 | |
| Long term follow-up | ||||||||
| 6 months | 5.9 (6.8) | 6.8 (5.9) | 7 (10) | 12 (14) | 95 (8) | 93 (13) | Not tested | Not tested |
| N = 35 | N = 33 | N = 34 | N = 31 | N = 35 | N = 33 | |||
| 12 months | 4.1 (6.7) | 3.7 (4.6) | 4 (7) | 9 (18) | 95 (10) | 95 (10) | Not tested | Not tested |
| N = 35 | N = 30 | N = 33 | N = 29 | N = 33 | N = 29 | |||